Clinical Trial Title
Pazopanib neoadjuvant trial in non-rhabdomyosarcoma soft tissue sarcomas (PAZNTIS): A phase II/III randomized trial of preoperative chemoradiation or preoperative radiation plus or minus pazopanib.Clinical Trial Protocol Description:
To identify the dose of pazopanib that is feasible when given in combination with radiation or chemo-radiation in pediatric and adult patients with unresected intermediate- and high-risk NRSTS.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are older than 2 years of age at the time of the biopsy that established the diagnosis of NRSTS.
- Have been newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk. Patients will be eligible for the chemotherapy or non-chemotherapy cohort based on:
- Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials.
- Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade.
This is a partial list of elgibility requirements.
Study Details
Clinical Trial Investigator
Mary Lou Schmidt, MD
Contact Information
Rush Cancer Center Clinical Trials Office